TLSI
TriSalus Life Sciences, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
5.27
▲ 0.04 (0.76%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
5.13
Prev close
5.23
Day high
5.35
Day low
5.18
Volume
98.69K
Market cap
$324.50M
P/E (TTM)
—
52W range
2.20 – 7.95
Day trading desk
Gap from prior close
-1.91%
Prior close 5.23
VWAP
5.26
+0.24% from price
Relative volume
0.31×
Quiet session
Session range
4.29%
5.13 – 5.35
Position in range
64%
Mid range
ATR (14D)
0.37
6.95% of price
Prior day high
5.43
PDH
Prior day low
5.22
PDL
Bid / ask spread
—
Quote not published
Session volume
99.49K
Avg 317.99K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
0.00%
+1.4%
1M
+23.42%
+19.7%
3M
+52.75%
+49.7%
6M
-3.30%
-14.4%
YTD
-24.50%
-36.8%
1Y
+2.93%
-17.1%
3Y
-52.74%
-126.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TLSI open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+2.16M
Net buying
Buy transactions
18
2.19M shares
Sell transactions
6
34.22K shares
Net transactions
+24
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
20.91M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | SZELA MARY T. Chief Executive Officer |
STOCK | 3.99K | $15.44K | Direct |
| Jun 30, 26 | MARSHAK RICHARD Officer |
STOCK | 561 | $2.17K | Direct |
| Jun 29, 26 | MARSHALL RICHARD HENRY Officer |
STOCK | 60.00K | $0 | Direct |
| May 15, 26 | STANSKY MICHAEL P Director |
BUY | 610.00K | $1.52M | |
| May 15, 26 | SZELA MARY T. Chief Executive Officer |
BUY | 39.68K | $102.78K | Direct |
| May 15, 26 | WAHLSTROM MATS Director |
BUY | 60.00K | $151.80K | Direct |
| May 15, 26 | GORDON GARY B Director |
BUY | 10.00K | $24.60K | Direct |
| May 15, 26 | PATIENCE DAVID Chief Financial Officer |
BUY | 7.10K | $17.25K | Direct |
| May 15, 26 | MARSHAK RICHARD Officer |
SELL | 543 | $1.45K | Direct |
| May 14, 26 | HICKS KERRY R Director |
STOCK | 28.20K | $0 | Direct |
| May 14, 26 | STANSKY MICHAEL P Director |
STOCK | 43.59K | $0 | Direct |
| May 14, 26 | MATLIN DAVID J. Director |
STOCK | 51.27K | $0 | Direct |
| May 14, 26 | WAHLSTROM MATS Director |
STOCK | 71.83K | $0 | Direct |
| May 14, 26 | GORDON GARY B Director |
STOCK | 52.75K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FRANKENIUS EQUITY AB |
Beneficial Owner of more than 10% of a Class of Security | 6.99M | Conversion of Exercise of derivative security |
HICKS KERRY R |
Director | 2.32M | Stock Award(Grant) |
MARTIN GEORGE KELLY |
Director | — | Sale |
MATLIN DAVID J. |
Director | 1.32M | Stock Award(Grant) |
MURPHY SEAN EDWARD |
Director | 679.26K | Stock Award(Grant) |
PATIENCE DAVID |
Chief Financial Officer | 275.76K | Purchase |
STANSKY MICHAEL P |
Director | — | Purchase |
STANSKY MICHAEL P. CPA |
Director | — | Purchase |
SZELA MARY T. |
Chief Executive Officer | 1.08M | Stock Award(Grant) |
WAHLSTROM MATS |
Director | 2.96M | Purchase |
Fundamentals
Market cap$324.50M
Enterprise value$312.64M
Revenue (TTM)$45.08M
Gross profit$38.67M
EBITDA$-29.95M
Net income$-57.25M
EPS (TTM)$-1.33
Free cash flow$-10.88M
Total cash$46.29M
Total debt$34.43M
Book value / share$0.11
Shares outstanding61.57M
Float49.50M
Short % of float8.10%
Dividend yield—
Beta (5Y)0.43
Valuation & profitability ratios
Trailing P/E—
Forward P/E-21.08
PEG ratio—
Price / sales—
Price / book49.25
EV / revenue6.94
EV / EBITDA-10.44
Gross margin85.79%
Operating margin-86.03%
Profit margin-62.59%
Return on equity—
Return on assets-36.75%
Debt / equity525.59
Current ratio5.35
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $45.15M | $29.43M | $18.51M | $12.40M | +53.4% |
| Operating revenue | $45.15M | $29.43M | $18.51M | $12.40M | +53.4% |
| Cost of revenue | $6.96M | $4.10M | $2.60M | $2.26M | +69.8% |
| Gross profit | $38.19M | $25.33M | $15.91M | $10.14M | +50.8% |
| Research & development | $14.96M | $17.69M | $29.84M | $21.36M | -15.4% |
| Selling, general & admin | $50.17M | $43.80M | $40.55M | $25.22M | +14.5% |
| Total operating expense | $65.13M | $61.49M | $70.38M | $46.58M | +5.9% |
| Operating income | -$26.95M | -$36.16M | -$54.48M | -$36.44M | +25.5% |
| Net interest income | -$4.99M | -$2.69M | $415.00K | $179.00K | -85.7% |
| Pre-tax income | -$39.22M | -$30.04M | -$59.35M | -$47.18M | -30.6% |
| Tax provision | $7.00K | $6.00K | $9.00K | $9.00K | +16.7% |
| Net income | -$39.23M | -$30.05M | -$59.36M | -$47.19M | -30.6% |
| Net income to common | -$69.69M | -$33.23M | -$63.60M | -$50.02M | -109.7% |
| Basic EPS | -1.84 | -1.31 | -6.73 | -161.55 | -40.5% |
| Diluted EPS | -1.84 | -1.31 | -6.73 | -161.55 | -40.5% |
| EBIT | -$33.68M | -$26.95M | -$59.34M | -$47.18M | -25.0% |
| EBITDA | -$33.05M | -$26.20M | -$58.65M | -$46.78M | -26.1% |
| Basic shares | 37.90M | 25.33M | 9.40M | 309.61K | +49.6% |
| Diluted shares | 37.90M | 25.33M | 9.40M | 309.61K | +49.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.44M | $8.53M | $11.78M | $9.41M | — | +139.8% |
| Cash & short-term investments | $20.44M | $8.53M | $11.78M | $9.41M | — | +139.8% |
| Accounts receivable | $6.56M | $5.09M | $3.55M | $1.56M | — | +28.9% |
| Inventory | $3.08M | $4.05M | $2.54M | $1.47M | — | -24.0% |
| Total current assets | $32.24M | $20.67M | $20.86M | $17.21M | — | +56.0% |
| Property, plant & equipment | $2.67M | $2.88M | $3.27M | $3.61M | — | -7.3% |
| Goodwill & intangibles | — | — | $1.13M | $802.00K | $794.00K | — |
| Total assets | $35.33M | $23.97M | $24.60M | $22.00M | — | +47.4% |
| Total current liabilities | $11.50M | $10.23M | $14.69M | $32.36M | — | +12.4% |
| Long-term debt | $33.05M | $22.08M | — | — | — | +49.6% |
| Total debt | $34.44M | $23.63M | $1.59M | $1.96M | — | +45.8% |
| Total liabilities | $69.19M | $49.87M | $51.66M | $198.32M | — | +38.8% |
| Retained earnings | -$330.58M | -$279.55M | -$249.50M | -$186.36M | — | -18.3% |
| Shareholder equity | -$33.86M | -$25.89M | -$27.07M | -$176.33M | — | -30.8% |
| Working capital | $20.75M | $10.44M | $6.17M | -$15.14M | — | +98.7% |
| Net tangible assets | -$33.86M | -$25.89M | -$27.07M | -$177.13M | — | -30.8% |
| Shares issued | 50.00M | 31.28M | 26.41M | 26.32M | — | +59.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$39.23M | -$30.05M | -$59.36M | -$47.19M | -30.6% |
| Depreciation & amortisation | $626.00K | $744.00K | $684.00K | $398.00K | -15.9% |
| Stock-based compensation | $9.13M | $5.44M | $1.40M | $368.00K | +67.8% |
| Change in working capital | $2.07M | -$9.55M | $537.00K | $2.30M | +121.7% |
| Operating cash flow | -$18.01M | -$40.84M | -$50.58M | -$32.31M | +55.9% |
| Capital expenditure | -$918.00K | -$345.00K | -$588.00K | -$786.00K | -166.1% |
| Investing cash flow | -$838.00K | -$345.00K | -$1.59M | -$1.79M | -142.9% |
| Financing cash flow | $30.76M | $37.94M | $54.63M | $13.46M | -18.9% |
| Free cash flow | -$18.93M | -$41.19M | -$51.17M | -$33.10M | +54.0% |
| End cash position | $20.79M | $8.88M | $12.13M | $9.66M | +134.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $11.41M | $8.90M | $13.21M | $11.57M | $11.21M | +28.2% |
| Operating revenue | $11.41M | $8.90M | $13.21M | $11.57M | $11.21M | +28.2% |
| Cost of revenue | $1.51M | $1.23M | $1.76M | $1.91M | $1.80M | +22.6% |
| Gross profit | $9.90M | $7.67M | $11.44M | $9.66M | $9.41M | +29.1% |
| Research & development | $3.14M | $3.22M | $2.57M | $5.18M | $3.67M | -2.5% |
| Selling, general & admin | $16.57M | $12.86M | $12.14M | $13.50M | $13.07M | +28.8% |
| Total operating expense | $19.71M | $16.08M | $14.71M | $18.67M | $16.74M | +22.6% |
| Operating income | -$9.81M | -$8.41M | -$3.27M | -$9.01M | -$7.33M | -16.7% |
| Net interest income | -$1.03M | -$1.27M | -$1.27M | -$1.29M | -$1.29M | +18.8% |
| Pre-tax income | -$9.18M | $1.54M | -$9.75M | -$10.81M | -$8.29M | -695.1% |
| Tax provision | $4.00K | $4.00K | $0 | $5.00K | -$3.00K | 0.0% |
| Net income | -$9.19M | $1.54M | -$9.75M | -$10.81M | -$8.29M | -696.9% |
| Net income to common | -$9.19M | $1.54M | -$9.75M | -$41.27M | -$9.00M | -696.9% |
| Basic EPS | -0.16 | 0.03 | -0.21 | -0.96 | -0.27 | -633.3% |
| Diluted EPS | -0.16 | 0.03 | -0.21 | -0.96 | -0.27 | -633.3% |
| EBIT | -$7.69M | $2.98M | -$8.30M | -$9.35M | -$6.87M | -358.2% |
| EBITDA | -$7.56M | $3.11M | -$8.18M | -$9.18M | -$6.70M | -342.7% |
| Basic shares | 58.30M | 51.54M | 46.84M | 43.06M | 32.90M | +13.1% |
| Diluted shares | 58.30M | 52.31M | 46.84M | 43.06M | 32.90M | +11.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $46.29M | $56.55M | $20.44M | $22.69M | $26.49M | -18.2% |
| Cash & short-term investments | $46.29M | $56.55M | $20.44M | $22.69M | $26.49M | -18.2% |
| Accounts receivable | $6.46M | $5.21M | $6.56M | $5.00M | $5.57M | +23.9% |
| Inventory | $4.21M | $3.78M | $3.08M | $3.28M | $3.81M | +11.3% |
| Total current assets | $59.74M | $68.14M | $32.24M | $33.33M | $38.08M | -12.3% |
| Property, plant & equipment | $2.63M | $2.77M | $2.67M | $2.72M | $2.81M | -4.9% |
| Total assets | $62.45M | $70.98M | $35.33M | $36.46M | $41.32M | -12.0% |
| Total current liabilities | $11.17M | $11.79M | $11.50M | $10.91M | $9.32M | -5.2% |
| Long-term debt | $33.06M | $33.08M | $33.05M | $32.76M | $32.27M | -0.0% |
| Total debt | $34.43M | $34.49M | $34.44M | $34.12M | $33.66M | -0.2% |
| Total liabilities | $55.90M | $58.17M | $69.19M | $63.19M | $60.74M | -3.9% |
| Retained earnings | -$338.23M | -$329.04M | -$330.58M | -$320.97M | -$298.21M | -2.8% |
| Shareholder equity | $6.55M | $12.81M | -$33.86M | -$26.73M | -$19.42M | -48.9% |
| Working capital | $48.57M | $56.35M | $20.75M | $22.42M | $28.76M | -13.8% |
| Net tangible assets | $6.55M | $12.81M | -$33.86M | -$26.73M | -$19.42M | -48.9% |
| Shares issued | 61.47M | 61.41M | 50.00M | 49.89M | 37.98M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$9.19M | $1.54M | -$9.75M | -$10.81M | -$8.29M | — | -696.9% |
| Depreciation & amortisation | $136.00K | $135.00K | $126.00K | $163.00K | $165.00K | — | +0.7% |
| Stock-based compensation | $2.62M | $2.47M | $2.20M | $3.42M | $1.89M | — | +5.8% |
| Change in working capital | -$2.51M | $296.00K | -$530.00K | $2.39M | -$1.39M | — | -948.0% |
| Operating cash flow | -$10.13M | -$6.48M | -$2.48M | -$3.71M | -$7.32M | — | -56.3% |
| Capital expenditure | -$82.00K | -$141.00K | -$41.00K | -$216.00K | — | -$754.00K | +41.8% |
| Investing cash flow | -$82.00K | -$141.00K | -$41.00K | -$176.00K | $93.00K | — | +41.8% |
| Financing cash flow | -$54.00K | $42.38M | $277.00K | $82.00K | $20.72M | — | -100.1% |
| Free cash flow | -$10.21M | -$6.62M | -$2.52M | -$3.92M | -$7.23M | — | -54.2% |
| End cash position | $46.29M | $56.55M | $20.79M | $23.04M | $26.84M | — | -18.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.16 | -0.16 | -3.2% |
| Mar 2026 | -0.16 | — | — |
| Dec 2025 | -0.13 | -0.05 | +61.5% |
| Sep 2025 | -0.17 | -0.87 | -425.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.13 | 4 | $14.03M | +21.3% |
| Next quarter | -0.07 | 4 | $18.18M | +37.7% |
| Current year | -0.33 | 4 | $52.52M | +16.3% |
| Next year | -0.26 | 4 | $73.50M | +40.0% |
Analyst targets & ownership
Mean target$10.00
High target$14.00
Low target$7.00
Implied upside89.75%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy1 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders33.96%
Held by institutions35.71%
Institutions holding114
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.46
-3.46% from price
SMA 20
5.07
+4.04% from price
SMA 50
4.55
+15.84% from price
SMA 100
4.23
+24.50% from price
SMA 200
4.81
+9.62% from price
EMA 12
5.27
+0.06% from price
EMA 26
4.99
+5.72% from price
EMA 50
4.68
+12.72% from price
RSI (14)
58.0
Neutral
MACD (12,26,9)
0.28
Hist -0.02
ATR (14)
0.37
6.95% of price
Realised vol 30D
59.5%
Annualised
Bollinger upper
6.04
20, 2σ
Bollinger lower
4.09
20, 2σ
50 / 200 cross
Death
4.55 vs 4.81
Trend bias
Above 200
+9.62%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.22
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
59.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-66.4%
Peak to trough
Max drawdown 5Y
-79.0%
Peak to trough
ATR 14
0.37
6.95% of price
Beta (reported)
0.43
5Y monthly, from filing
Short interest
Shares short
3.77M
Prior 3.08M
Change vs prior
+22.5%
Shorts adding
% of float
8.10%
Normal
% of shares out
6.14%
Against total outstanding
Days to cover
17.2
Crowded exit
Float
49.50M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 13, 26 | Lake Street | MAINTAINED | Buy | Buy |
| Mar 9, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 6, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Dec 17, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 28, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Feb 13, 25 | Lake Street | INITIATED | — | Buy |
| Jan 24, 25 | Roth MKM | MAINTAINED | Buy | Buy |
| Dec 17, 24 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Nov 15, 24 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Nov 11, 24 | Roth MKM | INITIATED | — | Buy |
| Oct 25, 24 | Northland Capital Markets | INITIATED | — | Outperform |
| Sep 16, 24 | Oppenheimer | INITIATED | — | Outperform |
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-05-14
Corporate Changes & Voting Matters
8-K · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-07
Annual Report to Shareholders
ARS · 2026-03-31
Offering Registrations
S-8 · 2026-03-10
Corporate Changes & Voting Matters
8-K · 2026-03-05
Headlines
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
MarketBeat · 6d ago
TriSalus Life Sciences Q2 Earnings Call Highlights
MarketBeat · 16d ago
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ...
GuruFocus.com · 17d ago
TriSalus Life Sciences Reports Second Quarter 2026 Results
Business Wire · 17d ago
Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Q2 2026 -- GF Value Sees 20% Upside
GuruFocus.com · 19d ago
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Business Wire · 25d ago
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
Business Wire · 38d ago
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
Zacks · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.